LENSAR Q2 revenue rises 18%, returns to profit

The company said sustained demand for its ALLY robotic cataract laser systems drove growth in placements and backlog.

Procedure revenue grew 23% year over year as surgeons increased use of ALLY systems.

Net income and adjusted EBITDA increased due to improved revenue, lower operating expenses, and a $1.1 million tariff refund.

The company did not provide specific financial guidance for future quarters or the full year.

The current average analyst rating on the shares is strong buy, with 2 "strong buy" or "buy" ratings, no "hold" ratings, and no "sell" or "strong sell" ratings.

The average consensus recommendation for the advanced medical equipment and technology peer group is buy.

Wall Street's median 12-month price target for LENSAR Inc is $8.50, about 35.1% above its August 12 closing price of $6.29.

LENSAR said second-quarter revenue rose 18% year over year, with recurring revenue up 20%.

Net income turned positive, helped by improved revenue and lower operating expenses.